Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4.
about
Hepatitis C genotype 4: The past, present, and futureMetabolic factors and chronic hepatitis C: a complex interplayAn update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver.Prior to the oral therapy, what do we know about HCV-4 in Egypt: a randomized survey of prevalence and risks using data mining computed analysis.The association of IL28B genotype with the histological features of chronic hepatitis C is HCV genotype dependent.Genotype 4 HCV infection is difficult to cure with pegylated interferon and ribavirin. Results from a Greek Nationwide Cohort Study.The efficacy of a Hansenula-derived 20 kDa pegylated interferon alpha-2a in the treatment of genotype 4 chronic hepatitis C.Meta-analysis: influence of host and viral factors in patients with chronic hepatitis C genotype 4 treated with pegylated interferon and ribavirin.Test of IL28B polymorphisms in chronic hepatitis C patients treated with PegIFN and ribavirin depends on HCV genotypes: results from a meta-analysis.Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C.The impact of interleukin 28b gene polymorphism on the virological response to combined pegylated interferon and ribavirin therapy in chronic HCV genotype 4 infected egyptian patients using data mining analysisIL-28B polymorphisms correlated with treatment response in HCV-4 mono-infected patients: a meta-analysis.Predictors of Pegylated Interferon Alpha and Ribavirin Efficacy and Long-Term Assessment of Relapse in Patients With Chronic Hepatitis C: A One-Center Experience From ChinaPretreatment Predictors of Response to PegIFN-RBV Therapy in Egyptian Patients with HCV Genotype 4.Sustained virological response and its treatment predictors in hepatitis C virus genotype 4 compared to genotypes 1, 2, and 3: a meta-analysis.NS5A sequence heterogeneity of hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon-ribavirin therapy in Egyptian patientsHost genetic variants in the pathogenesis of hepatitis C.Interleukin-28 and hepatitis C virus genotype-4: treatment-induced clearance and liver fibrosis.Pharmacogenomics of hepatitis C infections: personalizing therapy.Individualized hepatocellular carcinoma risk: the challenges for designing successful chemoprevention strategies.IL28B polymorphisms predict the virological response to standard therapy in patients with chronic hepatitis C virus genotype 4 infection.Cirrhosis and rapid virological response to peginterferon plus ribavirin determine treatment outcome in HCV-1 IL28B rs12979860 CC patients.Interaction of IFNL3 with insulin resistance, steatosis and lipid metabolism in chronic hepatitis C virus infection.Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment.IL28B genotype is associated with cirrhosis or transition to cirrhosis in treatment-naive patients with chronic HCV genotype 1 infection: the international observational Gen-C study.Individualization of chronic hepatitis C treatment according to the host characteristics.Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection?IL28B polymorphisms as a pretreatment predictor of response to HCV treatment.How to optimize HCV therapy in genotype 2 patients.The role of pharmacogenetics in the treatment of chronic hepatitis C infection.Optimal therapy in genotype 4 chronic hepatitis C: finally cured?Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis.Polymorphisms at IL28B gene as predictors of viral relapse in genotype 4 Egyptian hepatitis C patients.Predictors of sustained virological response in Greek and Egyptian patients with hepatitis C genotype 4: does ethnicity matter?IL28B polymorphism, Explanation for Different Responses to Therapy in Hepatitis C Patients.IFNL3 (IL28B) and IFNL4 polymorphisms are associated with treatment response in Thai patients infected with HCV genotype 1, but not with genotypes 3 and 6.Interleukin 28B polymorphism predicts interferon plus ribavirin treatment outcome in patients with hepatitis C virus-related liver cirrhosis: A multicenter retrospective study in Japan.Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin.IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4.
P2860
Q26775815-65DFA6B3-14D0-484A-8D53-E3D91B145021Q27011787-88D44BBC-8D5B-4376-B774-FBFDEFBFAEB6Q30453975-79BE1AB9-BC70-49DB-BFFD-CF552345D478Q30881190-A9B7AA4A-CF70-4611-B821-714A35DB07DAQ33755525-88658151-B069-4B30-BA88-8BA6C4E254A3Q33918559-04C4884F-BCCD-4A54-9A6E-5B6377CECE88Q34113840-30373484-97FB-4004-9DA5-D21B9892878DQ34270336-843129F7-DCA1-469B-B951-E0940E06244DQ34429833-4459E7A6-54F8-47A9-B336-8241B098AE15Q34539324-8240749C-2356-47BF-9023-AD9AEF293D74Q34996891-1A0710CF-C64F-4D1C-8D05-AF64C392D229Q35124008-C79EE542-B65B-4E32-8636-B037FB8E3922Q35942041-F92DDF2D-0026-487B-AF23-A7F161B2E935Q35995923-4309E418-04FD-4C7F-A390-9888E1FC82F8Q36140466-B03CCE57-9EB6-41EF-BEF8-9CDE5045C6A1Q36414090-5FEDCDA4-6291-4D8F-B9BF-EE62F1CC1B07Q36482742-2ABE2DD8-7BEE-4803-904E-9AF30CEDF53DQ36492644-940CCD2F-5B8F-4795-A262-EAA367DA861EQ36632938-2B65A28D-833E-4E0B-8E01-16EC6776BA07Q36699256-C1D91E1C-84BB-491A-AD59-C1CB751D4FAEQ36963985-0106FCB6-6621-4B42-8956-42FBFC50ED72Q37044222-3465AD85-D3F9-4A56-97ED-050B99754BFEQ37285273-7C1EE232-F5C4-4D25-BF5F-053CC2AFF143Q37362755-E41B3E28-EBD2-4A11-A282-E389A1F54630Q37423627-C0C123D0-8818-4E03-9530-A9C5B847E095Q37654502-A7DA20BC-617D-4E98-899D-9BFD6655DD2FQ38042462-7FB5333F-3AC8-40D9-A092-5A4004F4A096Q38053543-BA1ABE9C-22BA-4845-A401-A86393CF3792Q38071386-30B40181-AABA-47B2-92D1-4CA4F546DEBEQ38151586-C305CB9F-7D2B-4B2F-8493-DC73FD7BBADFQ38295814-0D223306-9589-4E81-AECD-64BC20366849Q38445623-5C3B9636-D32C-4080-93D3-54A1344C8854Q38995225-20BFAC5D-BD36-4CBB-BF5F-DDA9DD101734Q39337505-E15DE80F-A864-459F-A39C-3DF0221021C0Q41251344-6E2147DA-CF3B-433E-87A4-E21693B44C3FQ42221315-6CAB8723-E342-46E8-B284-2AE7CC93DD8EQ42244565-6EB31233-70F6-494E-927A-896B82F95D4DQ42264136-C8A114DF-1204-4866-8D04-FF421D5A0318Q42980402-0611C92E-8F7F-4EE6-9C73-8041060E2BB6Q42987167-D7ECDA92-DE50-4E43-9D36-D87FFF87AF32
P2860
Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Interleukin 28B polymorphism p ...... hronic hepatitis C genotype 4.
@en
Interleukin 28B polymorphism p ...... hronic hepatitis C genotype 4.
@nl
type
label
Interleukin 28B polymorphism p ...... hronic hepatitis C genotype 4.
@en
Interleukin 28B polymorphism p ...... hronic hepatitis C genotype 4.
@nl
prefLabel
Interleukin 28B polymorphism p ...... hronic hepatitis C genotype 4.
@en
Interleukin 28B polymorphism p ...... hronic hepatitis C genotype 4.
@nl
P2093
P2860
P50
P356
P1433
P1476
Interleukin 28B polymorphism p ...... chronic hepatitis C genotype 4
@en
P2093
Cristina Cheroni
Enrico Galmozzi
Gian Maria Prati
Maria Francesca Donato
Massimo Colombo
Roberta Soffredini
Stella De Nicola
P2860
P304
P356
10.1002/HEP.24683
P407
P577
2012-01-03T00:00:00Z